To compare the efficacy and toxicities of chemotherapy plus cetuximab (Erbitux, E; E−chemo) with chemotherapy alone (chemo alone) in patients with previously untreated advanced non−small−cell lung cancer (NSCLC). The primary endpoint was overall survival; the secondary endpoints were progression−free survival, overall response rate, one−year survival and safety.
»
02/09/10